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We evaluated the sequential use of carboplatin, paclitaxel and topotecan in patients with advanced, previously untreated ovarian
cancer. In total, 43 patients with advanced ovarian cancer and 41cm residual disease were treated with sequential carboplatin (area-
under-the-curve (AUC) 5 days 1 and 22), paclitaxel (175mgm
 2 days 43 and 64) and topotecan (1.5mgm
 2 daily for 5 days from
days 85, 106, 127 and 148). Median age of patients was 61 years. Median follow-up was 22.2 months (range 0.76–50.6 months). In
all, 34 (79%) patients received all eight cycles of treatment and nine (21%) withdrew. Of the 29 evaluable patients, 19 (66%)
responded according to WHO and 30 of 36 (83%) patients according to CA125. The best overall response (CA125 and/or WHO)
was 77% (33 of 43 patients). The response rates to sequential drugs based on 450% fall in CA125 were as follows: carboplatin, 77%
(30 of 39 patients); paclitaxel, 65% (15 of 23 patients); topotecan, 38% (five of 13 patients). Two patients responded to paclitaxel and
one to topotecan after failure to respond to preceding chemotherapy. Median survival and time to progression was 22.24 and 10.61
months, respectively. This study demonstrates that sequential chemotherapy with just two initial courses of carboplatin is a
reasonable way to introduce new agents into first-line therapy for poor prognostic ovarian cancer patients.
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Ovarian cancer remains the leading cause of death from
gynaecological malignancy in Europe and North America (Pisani
et al, 1999). Surgical cytoreduction followed by systemic che-
motherapy forms the main stay of treatment for patients with
advanced disease, with initial objective response rates ranging
from 60 to 80% (Markman and Hoskins, 1992). Unfortunately, the
majority of women with advanced disease relapse and the overall
5-year survival remain less than 30% (Averette and Donato, 1990).
Consequently, alternative chemotherapy regimens are urgently
required to improve these disappointing survival statistics.
Combination chemotherapy with paclitaxel and carboplatin or
single-agent carboplatin are regarded as the standard of care as
first-line treatment for ovarian cancer (NICE Guidelines, 2003).
However, the improvement in survival of combination platinum-
containing regimens over single-agent platinum has been ques-
tioned by two large randomised trials. The ICON3 trial (ICON
Group, 2002) compared paclitaxel and carboplatin with a reference
arm of either single-agent carboplatin or a combination of
cyclophosphamide, adriamycin and cisplatin in 2074 patients,
and showed no difference in overall survival between the reference
and the paclitaxel-containing arms (HR¼0.98, 95% CI 0.87–1.10).
The GOG-132 trial (Muggia et al, 2000) compared single-agent
paclitaxel and single-agent cisplatin with the two drugs combined
in 648 patients and also showed no difference in overall survival
between the two cisplatin-containing arms (HR¼1.06, 95% CI
0.895–1.30).
There is also uncertainty in the literature as to the optimum
number of treatment cycles (Lambert et al, 1997) and the optimum
platinum dose (Ngan et al, 1989; Kaye et al, 1996). With specific
regard to carboplatin dose intensity, two trials failed to show any
significant survival benefit between patients treated with an area-
under-the-curve (AUC) of 4 or 8 (Jakobsen et al, 1997) or AUC 6 or
12 (Gore et al, 1998).
Incorporating new, potentially noncross resistant agents into
first-line combinations has the advantage of exposing tumour
cells to all drugs simultaneously and theoretically preventing the
emergence of drug-resistance clones. However, toxicity is
often severe and doses need to be reduced. An alternative strategy
involves sequential treatment with individual drugs. This approach
has the advantage of eliminating the additive toxicity of combined
drugs and also permits full dosages of each drug. Moreover, as
the tumour becomes resistant to one drug, treatment with
a nonresistant second drug should overcome the problem
of resistant clones. Interestingly, in vitro fibroblast models
with p53 mutations have been found to be hypersensitive to
paclitaxel but resistant to platinum, while cell lines with normal
p53 function are most sensitive to platinum (Wahl et al, 1996).
Therefore, by using sequential treatment with platinum followed
by a taxane, one would expect the population of p53-competent
tumour cells to be eradicated by the initial platinum, leaving a
second population of predominantly mutant p53 cells highly
sensitive to the taxane.
Extending the platinum-free interval in recurrent ovarian cancer
by using a noncross resistant chemotherapy agent at first relapse
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lmay have the advantage of increasing the response rate to
platinum reinduction on further progression (Kavanagh et al,
1996). Within this study, therefore, we might expect an increased
response rate to second-line platinum-containing regimens
following sequential paclitaxel and topotecan.
There is some evidence from preclinical models that therapeutic
synergy occurs when combining platinum with paclitaxel
or topotecan (Kamazawa et al, 2000), and therefore a potential
disadvantage of sequential therapy would be the loss of antitumour
activity. This disadvantage, however, was not seen in a
recent phase III trial comparing sequential single-agent doxor-
ubicin and paclitaxel to combination doxorubicin and paclitaxel in
metastatic breast cancer patients. Although inferior overall
response rates and time to progression were seen in the sequential
arm, there was no significant difference in overall survival (Sledge
et al, 2003).
Topotecan, a topoisomerase-1 inhibitor, has been extensively
tested in recurrent ovarian cancer and has shown a 13.4% response
rate using a intravenous (i.v.) dose of 1.5mgm
 2 daily for 5 days
(Gore et al, 2002). However, bone marrow suppression is
considerable, limiting its use in combination with other che-
motherapeutic agents.
This phase II trial was therefore designed to assess the
feasibility and the response rates of sequential chemotherapy
using the commonly used doses of carboplatin, paclitaxel
and topotecan as first-line treatment for advanced ovarian cancer
patients.
PATIENTS AND METHODS
Patient eligibility
All patients had histologically confirmed advanced epithelial
ovarian cancer (FIGO stage IIB, IIIA, IIIB, IIIC or IV) and
41cm residual disease at the completion of initial surgery.
Diagnostic surgery had to be performed o6 weeks prior to entry
to the study. Eligible patients had not received previous
chemotherapy, radiotherapy or hormonal therapy, had a perfor-
mance status of o2 (European Co-operative Oncology Group,
ECOG Scale), were between 18 and 75 years of age, had a life
expectancy of 412 weeks and were required to have adequate
haematological (neutrophil count 41.5 10
9l
 1; platelet count
4100 10
9l
 1; haemoglobin 49.0gdl
 1), renal (serum creatinine
o2 ULN, EDTA clearance 450mlmin
 1) and hepatic (alkaline
phosphatase and alanine transaminase o2.5 ULN if no liver
metastases present or o5 ULN if liver metastases are present)
functions. Patients with uncontrolled infection, concurrent severe
medical conditions, pre-existing motor or sensory neurotoxicity
(4grade 2 according to National Cancer Institute-Common
Toxicity Criteria (NCI-CTC)) and history of previous malignancies
were excluded.
The protocol was approved by the Ethics Review Committees of
the two cancer centres. Written informed consent was obtained
from each patient before accrual.
Study design
This was a phase II study conducted between two cancer
centres. In all, 40 evaluable patients were required to show a
70% response rate using confidence intervals of 56–84%.
The treatment consisted of sequential carboplatin given as an i.v.
infusion over 60min on days 1 and 22, followed by paclitaxel,
175mgm
 2 given over 3h on days 43 and 64 and topotecan,
1.5mgm
 2 given over 30min for 5 days from days 85, 106, 127
and 148. The dose of carboplatin was calculated according to
the AUC method (Calvert et al, 1987), that is, 5(GFRþ25)mg,
where GFR is the glomerular filtration rate calculated using
5Cr
EDTA. A full blood count was performed prior to each course
of carboplatin and paclitaxel, but weekly during topotecan. Dose
reductions were based on the day 22 blood count after carboplatin
or paclitaxel, but on nadir counts after topotecan. Dose reductions
of carboplatin and/or paclitaxel were carried out according to the
following haematological toxicities: 10% dose reduction after
recovery from grade 1 thrombocytopenia, or grade 2 neutropenia,
25% dose reduction after recovery from grade 2 thrombocytope-
nia, or grade 3 neutropenia and 50% after recovery from grade 3
thrombocytopenia and grade 4 neutropenia. The paclitaxel dose
was also reduced by 50% if there was sustained grade 3 peripheral
neuropathy. The daily infusion dose of topotecan was reduced by
0.25mgm
 2day
 1 if a neutrophil nadir of o0.5 10
9l
 1 was
associated with fever or infection or lasted 47 days or if a
neutrophil nadir of 0.5–0.9 10
9l
 1 lasted beyond day 28 of the
treatment course or if there was a platelet nadir count of
o25 10
9l
 1. All patients continued on the same dose reduction
for each drug for the remainder of the study. Study treatment was
discontinued if haematological toxicity persisted after a maximum
2-week delay.
All patients had a physical examination, CA125 level, chest X-
ray and abdominal/pelvic CT scan prior to the start of treatment.
Disease was reassessed by repeat physical examinations and CA125
levels prior to each chemotherapy cycle and repeat CT scans on the
completion of cycles 4 and 8 in those patients with measurable
disease according to the World Health Organisation (WHO)
criteria (WHO handbook, 1979).
Response assessment
Tumour response was assessed in those patients with measurable
disease using the World Health Organisation criteria. To increase
the proportion of evaluable patients those with CA 125 levels
4120Uml
 1 postsurgery and prechemotherapy, were also
assessed according to precise CA125 criteria. A CA125 response
had occurred if there was either a 50 or 75% decrease in CA125
levels using a ‘CA125 evaluation’ computer programme (Rustin
et al, 1996a; Rustin et al, 2000). A 50% response occurred if after
two initial elevated samples there had been a 50% decrease of
serum CA 125 levels, confirmed by a fourth sample. A 75%
response occurred if there has been a serial decrease of serum CA
125 levels over three samples of at least 75%. In both 50 and 75%
definitions, the final sample had to be at least 28 days after the
previous sample.
Progression was defined either by WHO criteria or by
CA 125. The previously validated CA125 progression criteria
(Rustin et al, 1996b, 2001; Vergote et al, 2000) is defined as either
a doubling of the CA 125 levels from the nadir value achieved
during previous therapy or a doubling from the upper limit
of normal. (Value defined at local laboratories.) In each definition,
the rise in CA125 was confirmed with a second sample. The date
of progression was the date of the earliest event indicating
progression either according to CA125 or WHO criteria.
Progression-free survival was defined as the time between the
start of treatment and the date of first documented progression.
Overall survival was the time between the start of treatment and
death.
RESULTS
In total, 43 patients were entered into this phase II study across
two cancer centres between April 1998 and June 2001. The patient
characteristics of all patients are listed in Table 1. A total of 34
(79%) patients completed the study. Of the nine (21%) patients
who withdrew, four had progressive disease, three died on
treatment (one due to a cerebrovascular event, one due to
neutropenic sepsis, one due to peritonitis), one had a severe
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lallergic reaction to paclitaxel and one refused further chemother-
apy after interval debulking surgery.
Toxicity
The worse grade of toxicity that was experienced by each patient
throughout each course of chemotherapy was recorded (Table 2).
Grade 3 or 4 haematological toxicity was low during both
carboplatin and paclitaxel cycles but high during topotecan.
Nonhaematological toxicity was minimal. In all, 16 patients (37%)
had at least one dose delay and 10 patients (23%) required at least
one dose reduction.
Response
The median duration of follow-up in this study was 22.2.
months (range: 0.76–50.6 months). In all, 36 patients
were evaluable for response by CA 125 criteria and 30 of these
achieved a response, giving an overall response rate of 83.3%.
Seven patients were nonevaluable for response according to CA125
criteria, five due to less than three samples being available
for analysis and two in whom all CA 125 values were o40Uml
 1.
A total of 29 patients had measurable disease according
to standard criteria and 19 of these achieved a response,
giving an overall response rate of 65.5%. Three patients were
not evaluable by either CA 125 or standard criteria, leaving 40
patients assessable by combined CA 125 and standard criteria.
Of these, 30 patients responded giving an overall response rate
of 75% in evaluable patients and 70% among all patients treated.
Response rates according to a 50% fall in CA125 levels for
evaluable patients were analysed for each individual drug.
Of 39 evaluable patients, 30 responded to carboplatin (76.9%),
15 of 23 evaluable patients responded to paclitaxel (65.2%) and
five of 13 responded to topotecan (38.4%). Six patients progressed
on treatment according to standard criteria (three progressed
on the interval scan after receiving carboplatin and paclitaxel,
and three had stable disease on the first scan, but showed
progression by the end of treatment scan) giving an overall
progression rate of 14%. Surgery also contributed to the CA125
response. Therefore, only patients with most resistant disease had
persistently elevated CA125 levels on commencement of paclitaxel
or topotecan.
The median overall survival was 22.2 months (Figure 1).
Survival in the study population is compared in these figures with
Table 1 Patient characteristics
Patient no. %
Age (years)
Median 61
Range 40–79
Performance status
01 2 2 8
12 2 5 6
29 1 6
FIGO stage
II 1 2
III 28 65
IV 14 33
Cell type
Serous 25 58
Endometrioid 6 14
Mucinous 2 5
Other 10 23
Measurable disease 29 67
Type of surgery
Biopsy only 11 26
Debulk (41cm at close) 32 75
Table 2 Grade 3+4 toxicity (number and % of patients and courses with toxicity)
Carboplatin Paclitaxel Topotecan
Total patients,
N¼43 %
Total courses,
N¼85 %
Total patients,
N¼41 %
Total courses,
N¼80 %
Total patients,
N¼38 %
Total courses,
N¼145 %
Nonhaematological
Nausea/vomiting 3 7 2 2 0 0 0 0 1 3 1 1
Mucositis 0 0 0 0 1 2 1 1 0 0 0 0
Diarrhoea 1 2 1 1 0 0 0 0 2 5 2 1
Alopecia 0 0 0 0 15 37 22 28 18 47 72 50
Thromboembolic event 2 5 2 2 1 2 2 3 0 0 0 0
Haematological
Anaemia 1 2 1 1 2 5 2 3 6 16 6 4
Neutropenia 2 5 0 0 2 5 3 4 31 82 88 61
Neutropenic sepsis 2 5 2 2 2 5 2 3 5 13 8 6
Thrombocytopenia 1 2 1 1 0 0 1 1 4 11 5 3
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North Thames ovary, N = 236
 = 2.749
 P-value = 0.0973
Median sequential, 22.24 months
Median North Thames, 17.08 months
70 35
Figure 1 Overall survival in study patients compared to historical
matched group from North Thames Ovary Trials 3þ4( 42cm and
inoperable).
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lthat of a matched group of patients from two previous North
Thames ovary trials and found to be similar (Lambert et al, 1993;
Lambert et al, 1997). In this group, all patients had inoperable
disease or measurable disease 42cm at the end of surgery and
received between five and eight cycles of carboplatin. The
progression-free survival using both CA 125 and standard criteria
to define progression was 10.61 months in the current trial
compared to 10.45 months in the matched groups from the North
Thames trials.
In the present study, 21 patients from the initial response
group relapsed and went on to receive second-line chemotherapy
(17 patients received single-agent carboplatin, two received
carboplatin and paclitaxel, one received weekly cisplatin
and etoposide (van der Burg et al, 2002) and one received
altretamine). Seven of 14 evaluable patients responded to
second-line platinum-containing chemotherapy according
to CA125 criteria. Two of four evaluable patients relapsing
within 6 months of completing carboplatin responded, while
five of 10 evaluable patients relapsing beyond 6 months
responded. The majority of patients (75%) received
second-line chemotherapy 6 months or more from their initial
carboplatin.
DISCUSSION
To our knowledge this is the first published phase II trial
of sequential chemotherapy in advanced ovarian cancer
patients. However, in the previously reported Gynaecologic
Oncology Trial (GOG-132), the vast majority of patients (85%)
who relapsed on the single-agent arms went on to receive the
other drug, thereby effectively receiving sequential carboplatin
and paclitaxel chemotherapy (Muggia et al, 2000). Comparison
of the patient characteristics from this trial with those of the
above study show that although the two groups appear similar,
the overall and progression-free survival are slightly inferior
for the current phase II study. Reasons for this difference may be
reflected in the extent of surgery undertaken or the amount of
platinum chemotherapy each patient received. In both studies all
patients were suboptimally debulked, but in the current trial, 25%
of patients were only able to have a diagnostic biopsy at
laparotomy.
Comparison of the survival data from our study with that
of a matched population of patients with suboptimally debulked,
advanced ovarian cancer, all of whom received between five
and eight cycles of carboplatin (Lambert et al, 1993, 1997),
were identical. Therefore, it is plausible that patients in the current
study were not disadvantaged by receiving only two cycles
of carboplatin. This trial was planned at a time when the
GOG were running the 132 trial with single-agent paclitaxel
as one arm, which was later shown to have equivalent survival
to the platinum-containing arms (Muggia et al, 2000), implying
that initial platinum therapy is not essential. Rather than
give just six cycles of paclitaxel or six cycles of carboplatin
as in ICON 3 (ICON group 2002), it seemed reasonable to give
just two courses carboplatin prior to two courses of paclitaxel
and then to follow this with topotecan. This is the true test of
sequential therapy as if the standard total dose of carboplatin is
given, adding other drugs later leads to greatly prolonged
therapy, which could be almost considered maintenance therapy.
Furthermore very few patients would have any evaluable disease
left after completing full dose carboplatin. It is refreshing that
at a time when most oncologists wish to give more intense
combination therapy and are extending the number of courses,
a less intense regimen dose appears not to be deleterious.
Single-agent topotecan has been investigated extensively
for its use in relapsed ovarian cancer, with response rates in
platinum-sensitive patients ranging between 13 and 33% (Cree-
mers et al, 1996; ten Bokkel Huinink et al, 1997; Bookman et al,
1998; Gore et al, 2002). Much work has also been carried out
on whether using topotecan in first relapse can increase the
platinum-free interval, and thus subsequent responses rates
to platinum-containing regimens. One might speculate there-
fore that sequential use of topotecan may also increase the
treatment-free interval as well as the response rate to second-line
carboplatin. However, in this study although 15 out of 21 (71%)
patients who initially responded relapsed 6 months or more
after receiving carboplatin, the response rates to second-
line platinum were 50% according to CA125 criteria in
both platinum-resistant and platinum-responsive groups of
patients. These responses are similar to those seen in
previous studies so it is impossible to deduce that this response
rate was affected by the low dose of initial carboplatin or the
prolongation of platinum-free interval by the paclitaxel
and topotecan.
Individual drug response rates were analysed according to a
50% fall in CA125 levels and found to deteriorate with each
sequential drug. However, this is probably best explained by the
decline in the number of evaluable patients required for the CA125
response criteria for each individual drug as the study progressed.
Toxicity of this regimen was acceptable. Although a high
proportion of patients experienced haematological toxicity while
on topotecan, (82% of patients had grade 3 or 4 neutropenia) only
a small proportion (13%) required admission for neutropenic
sepsis. In addition, dose reductions were only necessary in 10
(23%) patients.
Several randomised trials are currently investigating sequential
chemotherapy as first-line treatment for ovarian cancer. The
recently closed SCOTROC (Scottish Randomised Trials in Ovarian
Cancer) 2A trial randomised 125 patients to receive four cycles
of carboplatin, AUC 7, q21d followed by either four cycles
docetaxel 100mgm
 2 q21d, four cycles docetaxel 75mgm
 2 (d8)
plus gemcitabine 1250mgm
 2 (d1/8) q21d or 12 weeks docetaxel
25mgm
 2 plus gemcitabine 800mgm
 2 q1wk. Survival data
are not yet mature; however, preliminary toxicity data suggested
that carboplatin followed by subsequent three-weekly docetaxel
with or without gemcitabine is feasible and safe. The
weekly docetaxel and gemcitabine arm, however, produced
significant delays and dose reductions (Rustin et al, 2002).
The International Collaborative Ovarian Neoplasm and Gynaeco-
logic Oncology Group trial groups are also currently investigating
sequential chemotherapy. In this trial (GOG-0182, MRC-ICON5)
patients will be randomised between the reference arm of eight
cycles paclitaxel and carboplatin, and triplet (gemcitabine or
pegylated liposomal doxorubicin with carboplatin and paclitaxel)
or sequential doublet (gemcitabine or topotecan with carboplatin
followed by carboplatin and paclitaxel) combinations. Approxi-
mately 6000 patients are required in this complex study in order to
detect a significant difference between each experimental arm and
the reference arm.
Both studies will use the previously validated CA125 criteria
(Rustin et al, 1996a,b) in addition to standard criteria to assess
response and overall survival. The arguments for assessing
response by either standard or CA125 criteria in ovarian cancer
have been convincingly made (Rustin 2003). Our study demon-
strates that analysing CA125 response to each individual drug is a
logical and quick means of determining the response rate of each
drug incorporated into the regimen.
In both of the above trials, patients receive a dose of carboplatin
equivalent to that given in standard single-agent or combination
regimens. The results of our trial suggest, however, that less
carboplatin can be safely given, allowing larger doses of new agents
to be tested. This phase II study has therefore shown that
sequential carboplatin followed by paclitaxel and topotecan is a
well-tolerated and effective regimen for advanced ovarian cancer.
This approach is being further investigated in ongoing randomised
clinical trials.
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